![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 09, 2018 9:43:55 PM
Does the manipulation of adipose derived autologous stem cell as is performed by USRM clinics enough for it to constitute a "drug" as defined by the regulations and thus bring it under the preview of the FDA?
KC and crew contend that it is not and have been looking for this fight since August of last year with their response to the warning letter. Not sure whether this injunction will be granted but we're definitely set for a legal showdown.
Either way, not good for business in the short term. In the long term, once this issue is resolved and if USRM comes out on top, USRM will cement it's place as the leader in the field. If USRM loses, well, there goes 33% of revenue stream until FDA figures out how to regulate this emerging field.
so, place your bets people.
Go USRM!!!
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM